The purpose of this research study is to determine how well BI3802876 is tolerated in people living with cirrhosis due to a liver condition called metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH). The study medication, BI3802876, is investigational, meaning it has not yet been approved by the United States Food and Drug…
This study aims to collect information about the symptoms and treatments of patients who have severely clogged arteries and are treated with commercially available Boston Scientific Corporation drug-eluting devices marketed for the treatment of lesions located in the peripheral vasculature. Participation in the study is expected to last for up to two (2)…